WE are all praying that these inhibitors work. The following may provide
some more insight as to progress of studies.
Dear All,
Hemoncdoc wrote:
"I believe the easiest explanation for why we hope
Endostatin/Angiostatin will far surpass these 1st generation inhibitors
is found in Dr. Folkman's chapter on angiogenesis in DeVita's Cancer
Medicine text. There Dr. Folkman gives a scale ranking of the %
inhibition of angiogenesis seen with various agents in one of the
commonly used murine tumor models. Where Thalidomide and Interferon
inhibit growth in the 30%-50% range, Endostatin/Angiostatin are
99-99.99% inhibitory."
Now, here is the scale Hemoncdoc referred to. Taken from CANCER:
Principles & Practice of Oncology, Volume 2, 5th Edition, by Vincent T.
DeVita, Jr., Samuel Hellman, and Steven A. Rosenberg.
Table 64-3. Antiangiogenic Therapy (Lewis Lung Carcinoma)
________________________________________________________________________
Year Inhibitor Treatment/Control %Inhibition
________________________________________________________________________
1980 Interferon-a/b 0.75 25
1982 Platelet factor 4 0.50 50
1990 TNP-470 0.35 65
1995 Interlukin-12 0.15 85
1994 Angiostatin (human) 0.13 87
1996 Angiostatin (mouse) 0.01 99
Unpublished Endostatin (mouse) 0.001 99
Note: In Dr. Folkman's internet speech, he noted that Lewis Lung
Carcinoma was one of most difficult to treat, and that is what was used
in this scale ranking.
God Bless
marty auslander
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
